Network approach in liquidomics landscape.

Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol settembre. 2017;14(9):531–48.

Poulet G, Massias J, Taly V. Liquid Biopsy: General Concepts. Acta Cytol. 2019;63(6):449–55.

pubmed: 31091522

Pantel K, Alix-Panabières C. Real-time liquid biopsy in cancer patients: fact or fiction? Cancer Res. 2013;73(21):6384–8.

pubmed: 24145355

Zhu JW, Charkhchi P, Akbari MR. Potential clinical utility of liquid biopsies in ovarian cancer. Mol Cancer. 2022;21(1):114.

pubmed: 35545786 pmcid: 9092780

Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang XHF, Norton L, et al. Tumor self-seeding by circulating cancer cells. Cell. 2009;139(7):1315–26.

pubmed: 20064377 pmcid: 2810531

Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer. 2004;4(6):448–56.

pubmed: 15170447

Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37(3):646–50.

pubmed: 837366

Mandel P, Metais P. Nuclear acids in human blood plasma. C R Seances Soc Biol Fil. 1948;142(3–4):241–3.

pubmed: 18875018

van der Pol Y, Mouliere F. Toward the early detection of cancer by decoding the epigenetic and environmental fingerprints of cell-free DNA. Cancer Cell. 2019;36(4):350–68.

pubmed: 31614115

Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 1994;3(1):67–71.

Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B, et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2006;12(13):3915–21.

Swisher EM, Wollan M, Mahtani SM, Willner JB, Garcia R, Goff BA, et al. Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. Am J Obstet Gynecol settembre. 2005;193(3 Pt 1):662–7.

Sozzi G, Musso K, Ratcliffe C, Goldstraw P, Pierotti MA, Pastorino U. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. Clin Cancer Res Off J Am Assoc Cancer Res. 1999;5(10):2689–92.

Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008;110(1):13–21.

pubmed: 18589210

Stevens GL, Scheer WD, Levine EA. Detection of tyrosinase mRNA from the blood of melanoma patients. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 1996;5(4):293–6.

Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles: artefacts no more. Trends Cell Biol. 2009;19(2):43–51.

pubmed: 19144520

Reckamp KL, Melnikova VO, Karlovich C, Sequist LV, Camidge DR, Wakelee H, et al. A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2016;11(10):1690–700.

Wang Y, Springer S, Mulvey CL, Silliman N, Schaefer J, Sausen M, et al. Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci Transl Med. 2015;7(293):293ra104.

pubmed: 26109104 pmcid: 4587492

Diehl F, Schmidt K, Durkee KH, Moore KJ, Goodman SN, Shuber AP, et al. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology. 2008;135(2):489–98.

pubmed: 18602395

Kuang Y, Rogers A, Yeap BY, Wang L, Makrigiorgos M, Vetrand K, et al. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15(8):2630–6.

Qian X, Liu J, Sun Y, Wang M, Lei H, Luo G, et al. Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer. Oncotarget. 2016;7(20):29154–65.

pubmed: 27081078 pmcid: 5045385

Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8(346):346ra92.

pubmed: 27384348 pmcid: 5346159

Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015;7(302):302ra133.

pubmed: 26311728

Salvianti F, Gelmini S, Costanza F, Mancini I, Sonnati G, Simi L, et al. The pre-analytical phase of the liquid biopsy. New Biotechnol. 2020;55:19–29.

Chan HT, Chin YM, Low SK. Circulating tumor DNA-based genomic profiling assays in adult solid tumors for precision oncology: recent advancements and future challenges. Cancers. 2022;14(13):3275.

pubmed: 35805046 pmcid: 9265547

Geeurickx E, Hendrix A. Targets, pitfalls and reference materials for liquid biopsy tests in cancer diagnostics. Mol Aspects Med. 2020;72:100828.

pubmed: 31711714

Neumann MHD, Bender S, Krahn T, Schlange T. ctDNA and CTCs in liquid biopsy - current status and where we need to progress. Comput Struct Biotechnol J. 2018;16:190–5.

pubmed: 29977481 pmcid: 6024152

Arechederra M, Ávila MA, Berasain C. Liquid biopsy for cancer management: a revolutionary but still limited new tool for precision medicine. Adv Lab Med Av En Med Lab. 1 settembre 2020 [citato 18 febbraio 2023];1(3). Disponibile su: https://www.degruyter.com/document/doi/10.1515/almed-2020-0009/html

Green SF. The cost of poor blood specimen quality and errors in preanalytical processes. Clin Biochem. 2013;46(13–14):1175–9.

pubmed: 23769816

Tsui DWY, Blumenthal GM, Philip R, Barrett JC, Montagut C, Bramlett K, et al. Development, validation, and regulatory considerations for a liquid biopsy test. Clin Chem. 2020;66(3):408–14.

pubmed: 32091082

Delgado PO, Alves BCA, Gehrke F de S, Kuniyoshi RK, Wroclavski ML, Del Giglio A, et al. Characterization of cell-free circulating DNA in plasma in patients with prostate cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2013;34(2):983–6.

Hashad D, Sorour A, Ghazal A, Talaat I. Free circulating tumor DNA as a diagnostic marker for breast cancer. J Clin Lab Anal. 2012;26(6):467–72.

pubmed: 23143630 pmcid: 6807470

Bettegowda C, Sausen M, Leary R, Kinde I, Agrawal N, Bartlett B, et al. Detection of circulating tumor dna in early and late stage human malignancies. Neuro-Oncol. 2014;16(suppl_3):iii7.

pmcid: 4144489

Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–90.

pubmed: 18670422

Morbelli S, Alama A, Ferrarazzo G, Coco S, Genova C, Rijavec E, et al. Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer: 18F-FDG PET/CT Study. J Nucl Med Off Publ Soc Nucl Med. 2017;58(11):1764–9.

Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24.

pubmed: 24553385 pmcid: 4017867

Umetani N, Kim J, Hiramatsu S, Reber HA, Hines OJ, Bilchik AJ, et al. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem. 2006;52(6):1062–9.

pubmed: 16723681

Chan KCA, Yeung SW, Lui WB, Rainer TH, Lo YMD. Effects of preanalytical factors on the molecular size of cell-free DNA in blood. Clin Chem aprile. 2005;51(4):781–4.

Swinkels DW, Wiegerinck E, Steegers EAP, de Kok JB. Effects of blood-processing protocols on cell-free DNA quantification in plasma. Clin Chem marzo. 2003;49(3):525–6.

Zapico A, Grassa A, Martínez E, Menéndez M, Cortés Prieto J. Endometrial resection and preoperative LH-RH agonists: a prospective 5-year trial. Eur J Obstet Gynecol Reprod Biol. 2005;119(1):114–8.

pubmed: 15734095

Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, et al. Circulating tumor DNA analysis in patients with cancer: American society of clinical oncology and college of American pathologists joint review. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(16):1631–41.

Grölz D, Hauch S, Schlumpberger M, Guenther K, Voss T, Sprenger-Haussels M, et al. Liquid biopsy preservation solutions for standardized pre-analytical workflows-venous whole blood and plasma. Curr Pathobiol Rep. 2018;6(4):275–86.

pubmed: 30595972 pmcid: 6290703

Sorber L, Zwaenepoel K, Jacobs J, De Winne K, Van Casteren K, Augustus E, et al. Specialized blood collection tubes for liquid biopsy: improving the pre-analytical conditions. Mol Diagn Ther. 2020;24(1):113–24.

pubmed: 31838654

Markus H, Contente-Cuomo T, Farooq M, Liang WS, Borad MJ, Sivakumar S, et al. Evaluation of pre-analytical factors affecting plasma DNA analysis. Sci Rep. 2018;8(1):7375.

pubmed: 29743667 pmcid: 5943304

El Messaoudi S, Rolet F, Mouliere F, Thierry AR. Circulating cell free DNA: Preanalytical considerations. Clin Chim Acta Int J Clin Chem. 2013;424:222–30.

Herrera LJ, Raja S, Gooding WE, El-Hefnawy T, Kelly L, Luketich JD, et al. Quantitative analysis of circulating plasma DNA as a tumor marker in thoracic malignancies. Clin Chem. 2005;51(1):113–8.

pubmed: 15539466

Sorber L, Zwaenepoel K, Deschoolmeester V, Roeyen G, Lardon F, Rolfo C, et al. A Comparison of Cell-Free DNA Isolation Kits: Isolation and Quantification of Cell-Free DNA in Plasma. J Mol Diagn JMD. 2017;19(1):162–8.

pubmed: 27865784

Bidard FC, Madic J, Mariani P, Piperno-Neumann S, Rampanou A, Servois V, et al. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int J Cancer. 2014;134(5):1207–13.

pubmed: 23934701

Sorber L, Zwaenepoel K, Deschoolmeester V, Van Schil PEY, Van Meerbeeck J, Lardon F, et al. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients. Lung Cancer Amst Neth. 2017;107:100–7.

Newman AM, Bratman SV, To J, Wynne JF, Eclov NCW, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20(5):548–54.

pubmed: 24705333 pmcid: 4016134

Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome Med. 2020;12(1):8.

pubmed: 31937368 pmcid: 6961404

Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, et al. Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2018;13(9):1248–68.

Pascual J, Attard G, Bidard FC, Curigliano G, De Mattos-Arruda L, Diehn M, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO precision medicine working group. Ann Oncol Off J Eur Soc Med Oncol. 2022;33(8):750–68.

Chan HT, Chin YM, Nakamura Y, Low SK. Clonal hematopoiesis in liquid biopsy: from biological noise to valuable clinical implications. Cancers. 2020;12(8):2277.

pubmed: 32823942 pmcid: 7463455

Mizuno K, Akamatsu S, Sumiyoshi T, Wong JH, Fujita M, Maejima K, et al. eVIDENCE: a practical variant filtering for low-frequency variants detection in cell-free DNA. Sci Rep. 2019;9(1):15017.

pubmed: 31641155 pmcid: 6805874

Chen I, Raymond VM, Geis JA, Collisson EA, Jensen BV, Hermann KL, et al. Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma. Oncotarget. 2017;8(58):97769–86.

pubmed: 29228650 pmcid: 5716690

Jacobs MT, Mohindra NA, Shantzer L, Chen IL, Phull H, Mitchell W, et al. Use of low-frequency driver mutations detected by cell-free circulating tumor DNA to guide targeted therapy in non–small-cell lung cancer: a multicenter case series. JCO Precis Oncol. 2018;2:1–10.

pubmed: 35135131

Razavi P, Li BT, Brown DN, Jung B, Hubbell E, Shen R, et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med. 2019;25(12):1928–37.

pubmed: 31768066 pmcid: 7061455

Tsao SCH, Weiss J, Hudson C, Christophi C, Cebon J, Behren A, et al. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations. Sci Rep. 2015;5:11198.

pubmed: 26095797

Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the college of American pathologists, the international association for the study of lung cancer, and the association for molecular pathology. Arch Pathol Lab Med. 2018;142(3):321–46.

pubmed: 29355391

Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol Off J Eur Soc Med Oncol. 2018;29(9):1895–902.

Chen M, Zhao H. Next-generation sequencing in liquid biopsy: cancer screening and early detection. Hum Genomics. 2019;13(1):34.

pubmed: 31370908 pmcid: 6669976

Rodríguez N, Viñal D, Rodríguez-Cobos J, De Castro J, Domínguez G. Genomic profiling in oncology clinical practice. Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex. 2020;22(9):1430–9.

Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(2):276–92.

Detection, Prevention, and Risk Reduction [Internet]. NCCN. [citato 26 marzo 2023]. Disponibile su: https://www.nccn.org/guidelines/category_2

Buglyó G, Styk J, Pös O, Csók Á, Repiska V, Soltész B, et al. Liquid biopsy as a source of nucleic acid biomarkers in the diagnosis and management of lynch syndrome. Int J Mol Sci. 2022;23(8):4284.

pubmed: 35457101 pmcid: 9029375

Meric-Bernstam F, Brusco L, Daniels M, Wathoo C, Bailey AM, Strong L, et al. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Ann Oncol Off J Eur Soc Med Oncol. 2016;27(5):795–800.

Mandelker D, Donoghue M, Talukdar S, Bandlamudi C, Srinivasan P, Vivek M, et al. Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO precision medicine working group. Ann Oncol Off J Eur Soc Med Oncol. 2019;30(8):1221–31.

Paramathas S, Guha T, Pugh TJ, Malkin D, Villani A. Considerations for the use of circulating tumor DNA sequencing as a screening tool in cancer predisposition syndromes. Pediatr Blood Cancer. 2020;67(12):e28758.

pubmed: 33047872

Sausen M, Phallen J, Adleff V, Jones S, Leary RJ, Barrett MT, et al. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun. 2015;6:7686.

pubmed: 26154128

Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63–89.

pubmed: 31068988 pmcid: 6497009

Hou J, Li X, Xie KP. Coupled liquid biopsy and bioinformatics for pancreatic cancer early detection and precision prognostication. Mol Cancer. 2021;20(1):34.

pubmed: 33593396 pmcid: 7888169

Kanikarla-Marie P, Lam M, Menter DG, Kopetz S. Platelets, circulating tumor cells, and the circulome. Cancer Metastasis Rev. 2017;36(2):235–48.

pubmed: 28667367

De Rubis G, Rajeev Krishnan S, Bebawy M. Liquid biopsies in cancer diagnosis, monitoring, and prognosis. Trends Pharmacol Sci. 2019;40(3):172–86.

pubmed: 30736982

Ahn HS, Ho JY, Yu J, Yeom J, Lee S, Hur SY, et al. Plasma protein biomarkers associated with higher ovarian cancer risk in BRCA1/2 carriers. Cancers. 2021;13(10):2300.

pubmed: 34064977 pmcid: 8150736

Bordin A, Chirivì M, Pagano F, Milan M, Iuliano M, Scaccia E, et al. Human platelet lysate-derived extracellular vesicles enhance angiogenesis through miR-126. Cell Prolif. 2022;55(11):e13312.

pubmed: 35946052 pmcid: 9628251

Angelini F, Pagano F, Bordin A, Milan M, Chimenti I, Peruzzi M, et al. The Impact of environmental factors in influencing epigenetics related to oxidative states in the cardiovascular system. Oxid Med Cell. 2017;2017:2712751.

Tito C, De Falco E, Rosa P, Iaiza A, Fazi F, Petrozza V, et al. Circulating micrornas from the molecular mechanisms to clinical biomarkers: a focus on the clear cell renal cell carcinoma. Genes. 2021;12(8):1154.

pubmed: 34440329 pmcid: 8391131

Kerachian MA, Azghandi M, Mozaffari-Jovin S, Thierry AR. Guidelines for pre-analytical conditions for assessing the methylation of circulating cell-free DNA. Clin Epigenetics. 2021;13(1):193.

pubmed: 34663458 pmcid: 8525023

Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV, CCGA Consortium. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol Off J Eur Soc Med Oncol. 2020;31(6):745–59.

Yang J, Xu R, Wang C, Qiu J, Ren B, You L. Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review. Cancer Commun Lond Engl. 2021;41(12):1257–74.

Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523(7559):177–82.

pubmed: 26106858 pmcid: 4825698

Okada T, Iwano H, Ono Y, Karasaki H, Sato T, Yamada M, et al. Utility of «liquid biopsy» using pancreatic juice for early detection of pancreatic cancer. Endosc Int Open. 2018;6(12):E1454–61.

pubmed: 30539069 pmcid: 6288761

Liu Y, Cheng L, Wang G, Lv J, He Y, Shao PL, et al. A nano-magnetic size selective cfDNA extraction platform for liquid biopsy with enhanced precision. J Chromatogr B Analyt Technol Biomed Life Sci. 2022;1199:123236.

pubmed: 35472714

Li X, Wang Q, Wang R. Roles of exosome genomic DNA in colorectal cancer. Front Pharmacol. 2022;13:923232.

pubmed: 35721181 pmcid: 9198365

Wang Y, Li L, Douville C, Cohen JD, Yen TT, Kinde I, et al. Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Sci Transl Med. 2018;10(433):eaap8793.

pubmed: 29563323 pmcid: 6320220

Zhong Y, Xu F, Wu J, Schubert J, Li MM. Application of next generation sequencing in laboratory medicine. Ann Lab Med. 2021;41(1):25–43.

pubmed: 32829577 pmcid: 7443516

Precision medicine improves outcomes in metastatic breast cancer. Nature. 7 settembre 2022 [citato 22 febbraio 2023]; Disponibile su: https://www.nature.com/articles/d41586-022-02276-9

Guttery DS, Page K, Hills A, Woodley L, Marchese SD, Rghebi B, et al. Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer. Clin Chem. 2015;61(7):974–82.

pubmed: 25979954

Cardinali B, De Luca G, Tasso R, Coco S, Garuti A, Buzzatti G, et al. Targeting PIK3CA actionable mutations in the circulome: a proof of concept in metastatic breast cancer. Int J Mol Sci. 2022;23(11):6320.

pubmed: 35682999 pmcid: 9181240

Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16(7):409–24.

pubmed: 30796368

Rushton AJ, Nteliopoulos G, Shaw JA, Coombes RC. A review of circulating tumour cell enrichment technologies. Cancers. 2021;13(5):970.

pubmed: 33652649 pmcid: 7956528

Moding EJ, Nabet BY, Alizadeh AA, Diehn M. Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease. Cancer Discov. 2021;11(12):2968–86.

pubmed: 34785539 pmcid: 8976700

Ishiba T, Hoffmann AC, Usher J, Elshimali Y, Sturdevant T, Dang M, et al. Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types. Biochem Biophys Res Commun. 2018;500(3):621–5.

pubmed: 29679564 pmcid: 9165692

Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15(2):81–94.

pubmed: 29115304

Bidard FC, Mathiot C, Delaloge S, Brain E, Giachetti S, de Cremoux P, et al. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol Off J Eur Soc Med Oncol. 2010;21(4):729–33.

Rack B, Schindlbeck C, Jückstock J, Andergassen U, Hepp P, Zwingers T, et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst. 2014;106(5).

Janni WJ, Rack B, Terstappen LWMM, Pierga JY, Taran FA, Fehm T, et al. Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2016;22(10):2583–93.

Riethdorf S, Müller V, Loibl S, Nekljudova V, Weber K, Huober J, et al. Prognostic impact of circulating tumor cells for breast cancer patients treated in the neoadjuvant «geparquattro» trial. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23(18):5384–93.

Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, et al. Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-analysis. J Natl Cancer Inst. 2018;110(6):560–7.

pubmed: 29659933

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111–21.

pubmed: 29860917 pmcid: 6172658

Goodman CR, Seagle BLL, Friedl TWP, Rack B, Lato K, Fink V, et al. Association of circulating tumor cell status with benefit of radiotherapy and survival in early-stage breast cancer. JAMA Oncol. 2018;4(8):e180163.

pubmed: 29800954 pmcid: 6143053

Trapp E, Janni W, Schindlbeck C, Jückstock J, Andergassen U, de Gregorio A, et al. Presence of circulating tumor cells in high-risk early breast cancer during follow-up and prognosis. J Natl Cancer Inst. 2019;111(4):380–7.

pubmed: 30312434

Bidard FC, Jacot W, Kiavue N, Dureau S, Kadi A, Brain E, et al. Efficacy of circulating tumor cell count-driven vs clinician-driven first-line therapy choice in hormone receptor-positive, ERBB2-negative metastatic breast cancer: The STIC CTC randomized clinical trial. JAMA Oncol. 2021;7(1):34–41.

pubmed: 33151266

Matikas A, Kotsakis A, Apostolaki S, Politaki H, Perraki M, Kalbakis K, et al. Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer. Br J Cancer. 2022;126(11):1563–9.

pubmed: 35145253 pmcid: 9130117

van Dalum G, Stam GJ, Scholten LFA, Mastboom WJB, Vermes I, Tibbe AGJ, et al. Importance of circulating tumor cells in newly diagnosed colorectal cancer. Int J Oncol. 2015;46(3):1361–8.

pubmed: 25572133

Hinz S, Hendricks A, Wittig A, Schafmayer C, Tepel J, Kalthoff H, et al. Detection of circulating tumor cells with CK20 RT-PCR is an independent negative prognostic marker in colon cancer patients - a prospective study. BMC Cancer. 2017;17(1):53.

pubmed: 28086834 pmcid: 5237158

Dizdar L, Fluegen G, van Dalum G, Honisch E, Neves RP, Niederacher D, et al. Detection of circulating tumor cells in colorectal cancer patients using the GILUPI Cell Collector: results from a prospective, single-center study. Mol Oncol. 2019;13(7):1548–58.

pubmed: 31116510 pmcid: 6599844

Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(12):1556–63.

Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(5):525–32.

Dorsey JF, Kao GD, MacArthur KM, Ju M, Steinmetz D, Wileyto EP, et al. Tracking viable circulating tumor cells (CTCs) in the peripheral blood of non-small cell lung cancer (NSCLC) patients undergoing definitive radiation therapy: pilot study results. Cancer. 2015;121(1):139–49.

pubmed: 25241991

Chinniah C, Aguarin L, Cheng P, Decesaris C, Cutillo A, Berman AT, et al. Early detection of recurrence in patients with locally advanced non-small-cell lung cancer via circulating tumor cell analysis. Clin Lung Cancer. 2019;20(5):384-390.e2.

pubmed: 31221522 pmcid: 6703908

Frick MA, Feigenberg SJ, Jean-Baptiste SR, Aguarin LA, Mendes A, Chinniah C, et al. Circulating tumor cells are associated with recurrent disease in patients with early-stage non-small cell lung cancer treated with stereotactic body radiotherapy. Clin Cancer Res Off J Am Assoc Cancer Res. 2020;26(10):2372–80.

Kuske A, Gorges TM, Tennstedt P, Tiebel AK, Pompe R, Preißer F, et al. Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients. Sci Rep. 2016;6(1):39736.

pubmed: 28000772 pmcid: 5175156

Salami SS, Singhal U, Spratt DE, Palapattu GS, Hollenbeck BK, Schonhoft JD, et al. Circulating Tumor Cells as a Predictor of Treatment Response in Clinically Localized Prostate Cancer. JCO Precis Oncol. 2019;3.

Rink M, Chun FK, Dahlem R, Soave A, Minner S, Hansen J, et al. Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. Eur Urol. 2012;61(4):810–7.

pubmed: 22277196

Gazzaniga P, Gradilone A, de Berardinis E, Busetto GM, Raimondi C, Gandini O, et al. Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a Cell Search analysis. Ann Oncol. 2012;23(9):2352–6.

pubmed: 22351740

Gazzaniga P, de Berardinis E, Raimondi C, Gradilone A, Busetto GM, De Falco E, et al. Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer. Int J Cancer. 2014;135(8):1978–82.

pubmed: 24599551

Nicolazzo C, Busetto GM, Gradilone A, Sperduti I, Del Giudice F, Loreni F, et al. Circulating tumor cells identify patients with super-high-risk non-muscle-invasive bladder cancer: updated outcome analysis of a prospective single-center trial. Oncologist. 2019;24(5):612–6.

pubmed: 30944184 pmcid: 6516110

Busetto GM, Ferro M, Del Giudice F, Antonini G, Chung BI, Sperduti I, et al. The prognostic role of circulating tumor cells (CTC) in high-risk non–muscle-invasive bladder cancer. Clin Genitourin Cancer. 2017;15(4):e661–6.

pubmed: 28188046

Abrahamsson J, Aaltonen K, Engilbertsson H, Liedberg F, Patschan O, Rydén L, et al. Circulating tumor cells in patients with advanced urothelial carcinoma of the bladder: Association with tumor stage, lymph node metastases, FDG-PET findings, and survival. Urol Oncol Semin Orig Investig. 2017;35(10):606.e9-606.e16.

Soave A, Riethdorf S, Dahlem R, von Amsberg G, Minner S, Weisbach L, et al. A nonrandomized, prospective, clinical study on the impact of circulating tumor cells on outcomes of urothelial carcinoma of the bladder patients treated with radical cystectomy with or without adjuvant chemotherapy. Int J Cancer. 2017;140(2):381–9.

pubmed: 27668704

Beije N, de Kruijff IE, de Jong JJ, Klaver SO, de Vries P, Jacobs RAL, et al. Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. ESMO Open. 2022;7(2):100416.

pubmed: 35248823 pmcid: 9058916

Olsson E, Winter C, George A, Chen Y, Howlin J, Tang MHE, et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med. 2015;7(8):1034–47.

pubmed: 25987569 pmcid: 4551342

Chen YH, Hancock BA, Solzak JP, Brinza D, Scafe C, Miller KD, et al. Next-generation sequencing of circulating tumor DNA to predict recurrence in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy. Npj Breast Cancer. 2017;3(1):24.

pubmed: 28685160 pmcid: 5495776

Riva F, Bidard FC, Houy A, Saliou A, Madic J, Rampanou A, et al. Patient-specific circulating tumor DNA detection during neoadjuvant chemotherapy in triple-negative breast cancer. Clin Chem marzo. 2017;63(3):691–9.

McDonald BR, Contente-Cuomo T, Sammut SJ, Odenheimer-Bergman A, Ernst B, Perdigones N, et al. Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. Sci Transl Med. 2019;11(504).

Coombes RC, Page K, Salari R, Hastings RK, Armstrong A, Ahmed S, et al. Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25(14):4255–63.

Garcia-Murillas I, Chopra N, Comino-Méndez I, Beaney M, Tovey H, Cutts RJ, et al. Assessment of molecular relapse detection in early-stage breast cancer. JAMA Oncol. 2019;5(10):1473–8.

pubmed: 31369045 pmcid: 6681568

Parsons HA, Rhoades J, Reed SC, Gydush G, Ram P, Exman P, et al. Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2020;26(11):2556–64.

Magbanua MJM, Swigart LB, Wu HT, Hirst GL, Yau C, Wolf DM, et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol Off J Eur Soc Med Oncol. 2021;32(2):229–39.

Lipsyc-Sharf M, de Bruin EC, Santos K, McEwen R, Stetson D, Patel A, et al. Circulating tumor DNA and late recurrence in high-risk hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2022;40(22):2408–19.

Ng SB, Chua C, Ng M, Gan A, Poon PSY, Teo M, et al. Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery. Sci Rep. 2017;7(1):40737.

pubmed: 28102343 pmcid: 5244357

Schøler LV, Reinert T, Ørntoft MBW, Kassentoft CG, Árnadóttir SS, Vang S, et al. Clinical implications of monitoring circulating tumor DNA in patients with colorectal cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23(18):5437–45.

Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 2019;5(8):1124–31.

pubmed: 31070691 pmcid: 6512280

Tarazona N, Gimeno-Valiente F, Gambardella V, Zuñiga S, Rentero-Garrido P, Huerta M, et al. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. Ann Oncol Off J Eur Soc Med Oncol. 2019;30(11):1804–12.

Taieb J, Taly V, Vernerey D, Bourreau C, Bennouna J, Faroux R, et al. LBA30_PR - Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: prognostic and predictive value for adjuvant treatment duration. Ann Oncol. 2019;30:v867.

Tie J, Cohen JD, Lo SN, Wang Y, Li L, Christie M, et al. Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. Int J Cancer. 2021;148(4):1014–26.

pubmed: 32984952

Parikh AR, Van Seventer EE, Siravegna G, Hartwig AV, Jaimovich A, He Y, et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2021;27(20):5586–94.

Vidal J, Casadevall D, Bellosillo B, Pericay C, Garcia-Carbonero R, Losa F, et al. Clinical impact of presurgery circulating tumor DNA after total neoadjuvant treatment in locally advanced rectal cancer: a biomarker study from the GEMCAD 1402 trial. Clin Cancer Res Off J Am Assoc Cancer Res. 2021;27(10):2890–8.

Henriksen TV, Tarazona N, Frydendahl A, Reinert T, Gimeno-Valiente F, Carbonell-Asins JA, et al. Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences. Clin Cancer Res Off J Am Assoc Cancer Res. 2022;28(3):507–17.

Tie J, Cohen JD, Lahouel K, Lo SN, Wang Y, Kosmider S, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386(24):2261–72.

pubmed: 35657320 pmcid: 9701133

Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446–51.

pubmed: 28445469 pmcid: 5812436

Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov. 2017;7(12):1394–403.

pubmed: 28899864 pmcid: 5895851

Chen K, Zhao H, Shi Y, Yang F, Wang LT, Kang G, et al. Perioperative dynamic changes in circulating tumor DNA in patients with lung cancer (DYNAMIC). Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25(23):7058–67.

Xia L, Mei J, Kang R, Deng S, Chen Y, Yang Y, et al. Perioperative ctDNA-based molecular residual disease detection for non-small cell lung cancer: a prospective multicenter cohort study (LUNGCA-1). Clin Cancer Res Off J Am Assoc Cancer Res. 2022;28(15):3308–17.

Gale D, Heider K, Ruiz-Valdepenas A, Hackinger S, Perry M, Marsico G, et al. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer. Ann Oncol Off J Eur Soc Med Oncol. 2022;33(5):500–10.

Lau E, McCoy P, Reeves F, Chow K, Clarkson M, Kwan EM, et al. Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression. Genome Med agosto. 2020;12(1):72.

Powles T, Assaf ZJ, Davarpanah N, Banchereau R, Szabados BE, Yuen KC, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature. 2021;595(7867):432–7.

pubmed: 34135506

Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(4):525–37.

pubmed: 33721560 pmcid: 8495594

Nors J, Henriksen TV, Gotschalck KA, Juul T, Søgaard J, Iversen LH, et al. IMPROVE-IT2: implementing noninvasive circulating tumor DNA analysis to optimize the operative and postoperative treatment for patients with colorectal cancer - intervention trial 2. Study protocol. Vol. 59, Acta oncologica (Stockholm, Sweden). England; 2020. p. 336–41.

Kwapisz D. The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer? Ann Transl Med. 2017;5(3):46.

pubmed: 28251125 pmcid: 5326656

Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic - implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18(5):297–312.

pubmed: 33473219

Lemery S, Keegan P, Pazdur R. First FDA approval agnostic of cancer site - when a biomarker defines the indication. N Engl J Med. 2017;377(15):1409–12.

pubmed: 29020592

Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018;24(9):1441–8.

pubmed: 30082870

Kim ES, Velcheti V, Mekhail T, Yun C, Shagan SM, Hu S, et al. Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial. Nat Med. 2022;28(5):939–45.

pubmed: 35422531 pmcid: 9117143

Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic - implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18(5):297–312.

pubmed: 33473219

Willis J, Lefterova MI, Artyomenko A, Kasi PM, Nakamura Y, Mody K, et al. Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25(23):7035–45.

Odegaard JI, Vincent JJ, Mortimer S, Vowles JV, Ulrich BC, Banks KC, et al. Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue- and plasma-based methodologies. Clin Cancer Res Off J Am Assoc Cancer Res. 2018;24(15):3539–49.

Rolfo C, Drilon A, Hong D, McCoach C, Dowlati A, Lin JJ, et al. NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types. Br J Cancer. 2022;126(3):514–20.

pubmed: 34480094

Gonzalez-Cao M, Mayo-de-Las-Casas C, Molina-Vila MA, De Mattos-Arruda L, Muñoz-Couselo E, Manzano JL, et al. BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors. Melanoma Res. 2015;25(6):486–95.

pubmed: 26366702

El Messaoudi S, Mouliere F, Du Manoir S, Bascoul-Mollevi C, Gillet B, Nouaille M, et al. Circulating DNA as a strong multimarker prognostic tool for metastatic colorectal cancer patient management care. Clin Cancer Res Off J Am Assoc Cancer Res. 2016;22(12):3067–77.

Jacobs B, Claes B, Bachet JB, Bouche O, Sablon E, Maertens GG, et al. Evaluation of a fully automated extended RAS-BRAF test on prospectively collected plasma samples from patients with metastatic colorectal cancer. J Clin Oncol. 2017;35(15_suppl):e15127–e15127.

Bachet JB, Bouche O, Taïeb J, Dubreuil O, Garcia ML, Meurisse A, et al. RAS mutations concordance in circulating tumor DNA (ctDNA) and tissue in metastatic colorectal cancer (mCRC): RASANC, an AGEO prospective multicenter study. J Clin Oncol. 2017;35(15_suppl):11509–11509.

Esagian SM, Grigoriadou GΙ, Nikas IP, Boikou V, Sadow PM, Won JK, et al. Comparison of liquid-based to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: a comprehensive systematic review. J Cancer Res Clin Oncol. 2020;146(8):2051–66.

pubmed: 32462295 pmcid: 7456570

Kang KM, Muralidharan K, Yekula A, Small JL, Rosh ZS, Jones PS, et al. Blood-based detection of BRAF V600E in gliomas and brain tumor metastasis. Cancers. 2021;13(6):1227.

pubmed: 33799709 pmcid: 7998685

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.

pubmed: 26028255 pmcid: 4481136

Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25(13):3753–8.

Marcus L, Fashoyin-Aje LA, Donoghue M, Yuan M, Rodriguez L, Gallagher PS, et al. FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors. Clin Cancer Res Off J Am Assoc Cancer Res. 2021;27(17):4685–9.

Martin-Zanca D, Hughes SH, Barbacid M. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature. 1986;319(6056):743–8.

pubmed: 2869410

Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016;1(2):e000023.

pubmed: 27843590 pmcid: 5070277

Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15(12):731–47.

pubmed: 30333516 pmcid: 6419506

Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731–9.

pubmed: 29466156 pmcid: 5857389

Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21(2):271–82.

pubmed: 31838007

Rolfo C. NTRK gene fusions: a rough diamond ready to sparkle. Lancet Oncol. 2020;21(4):472–4.

pubmed: 32105623

Leicht DT, Balan V, Kaplun A, Singh-Gupta V, Kaplun L, Dobson M, et al. Raf kinases: function, regulation and role in human cancer. Biochim Biophys Acta. 2007;1773(8):1196–212.

pubmed: 17555829 pmcid: 1986673

Zaman A, Wu W, Bivona TG. Targeting oncogenic BRAF: past, present, and future. Cancers. 2019;11(8):1197.

pubmed: 31426419 pmcid: 6721448

Cohn AL, Day BM, Abhyankar S, McKenna E, Riehl T, Puzanov I. BRAFV600 mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study. OncoTargets Ther. 2017;10:965–71.

Oneal PA, Kwitkowski V, Luo L, Shen YL, Subramaniam S, Shord S, et al. FDA approval summary: vemurafenib for the treatment of patients with Erdheim-Chester disease with the BRAFV600 mutation. Oncologist. 2018;23(12):1520–4.

pubmed: 30120160 pmcid: 6292556

Bernocchi O, Sirico M, Corona SP, Strina C, Milani M, Cappelletti MR, et al. Tumor type agnostic therapy carrying BRAF mutation: case reports and review of literature. Pharm Basel Switz. 2021;14(2):159.

Mullard A. BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval. Nat Rev Drug Discov. 2022;21(8):548.

pubmed: 35794466

Subbiah V, Lassen U, Élez E, Italiano A, Curigliano G, Javle M, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020;21(9):1234–43.

pubmed: 32818466

Wen PY, Stein A, van den Bent M, De Greve J, Wick A, de Vos FYFL, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol. 2022;23(1):53–64.

pubmed: 34838156

Jenkins S, Yang JCH, Ramalingam SS, Yu K, Patel S, Weston S, et al. Plasma ctDNA analysis for detection of the EGFR T790M mutation in patients with advanced non-small cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2017;12(7):1061–70.

Schmiegel W, Scott RJ, Dooley S, Lewis W, Meldrum CJ, Pockney P, et al. Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing. Mol Oncol. 2017;11(2):208–19.

pubmed: 28106345 pmcid: 5527457

Vidal J, Muinelo L, Dalmases A, Jones F, Edelstein D, Iglesias M, et al. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann Oncol Off J Eur Soc Med Oncol. 2017;28(6):1325–32.

Kalemkerian GP, Narula N, Kennedy EB, Biermann WA, Donington J, Leighl NB, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American society of clinical oncology endorsement of the college of american pathologists/international association for the study of lung cancer/association for molecular pathology clinical practice guideline update. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(9):911–9.

Majem M, Juan O, Insa A, Reguart N, Trigo JM, Carcereny E, et al. SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex. 2019;21(1):3–17.

Ceccon C, Angerilli V, Rasola C, Procaccio L, Sabbadin M, Bergamo F, et al. Microsatellite instable colorectal adenocarcinoma diagnostics: the advent of liquid biopsy approaches. Front Oncol. 2022;12:930108.

pubmed: 35837109 pmcid: 9273960

Cescon DW, Bratman SV, Chan SM, Siu LL. Circulating tumor DNA and liquid biopsy in oncology. Nat Cancer. 2020;1(3):276–90.

pubmed: 35122035

Keller L, Belloum Y, Wikman H, Pantel K. Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. Br J Cancer. 2021;124(2):345–58.

pubmed: 32968207

Yu F, Makrigiorgos A, Leong KW, Makrigiorgos GM. Sensitive detection of microsatellite instability in tissues and liquid biopsies: Recent developments and updates. Comput Struct Biotechnol J. 2021;19:4931–40.

pubmed: 34527197 pmcid: 8433064

Russo A, Lopes AR, Scilla K, Mehra R, Adamo V, Oliveira J, et al. NTRK and NRG1 gene fusions in advanced non-small cell lung cancer (NSCLC). Precis Cancer Med. 2020 [citato 24 febbraio 2023];3(0). Disponibile su: https://pcm.amegroups.com/article/view/5551

Clark TA, Chung JH, Kennedy M, Hughes JD, Chennagiri N, Lieber DS, et al. Analytical validation of a hybrid capture-based next-generation sequencing clinical assay for genomic profiling of cell-free circulating tumor DNA. J Mol Diagn JMD. 2018;20(5):686–702.

pubmed: 29936259

André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929–40.

pubmed: 31091374

André F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol Off J Eur Soc Med Oncol. 2021;32(2):208–17.

Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JHM, et al. Phosphatidylinositol 3-Kinase α-selective inhibition with alpelisib (BYL719) in PIK3CA-Altered solid tumors: results from the first-in-human study. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(13):1291–9.

Rodon J, Curigliano G, Delord JP, Harb W, Azaro A, Han Y, et al. A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors. Oncotarget. 2018;9(60):31709–18.

pubmed: 30167089 pmcid: 6114962

Rolfo C, Cardona AF, Cristofanilli M, Paz-Ares L, Diaz Mochon JJ, Duran I, et al. Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). Crit Rev Oncol Hematol. 2020;151:102978.

pubmed: 32428812

Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21(7):795–801.

pubmed: 26030179 pmcid: 4868598

García-Foncillas J, Alba E, Aranda E, Díaz-Rubio E, López-López R, Tabernero J, et al. Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review. Ann Oncol Off J Eur Soc Med Oncol. 2017;28(12):2943–9.

Bachet JB, Bouché O, Taieb J, Dubreuil O, Garcia ML, Meurisse A, et al. RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study. Ann Oncol Off J Eur Soc Med Oncol. 2018;29(5):1211–9.

McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168(4):613–28.

pubmed: 28187284

Onidani K, Shoji H, Kakizaki T, Yoshimoto S, Okaya S, Miura N, et al. Monitoring of cancer patients via next-generation sequencing of patient-derived circulating tumor cells and tumor DNA. Cancer Sci. 2019;110(8):2590–9.

pubmed: 31169336 pmcid: 6676129

Osumi H, Shinozaki E, Yamaguchi K, Zembutsu H. Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer. Sci Rep. 2019;9(1):17358.

pubmed: 31758080 pmcid: 6874682

Ciardiello F, Normanno N, Martinelli E, Troiani T, Pisconti S, Cardone C, et al. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. Ann Oncol Off J Eur Soc Med Oncol. 2016;27(6):1055–61.

Normanno N, Esposito Abate R, Lambiase M, Forgione L, Cardone C, Iannaccone A, et al. RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial. Ann Oncol Off J Eur Soc Med Oncol. 2018;29(1):112–8.

Thierry AR, El Messaoudi S, Mollevi C, Raoul JL, Guimbaud R, Pezet D, et al. Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment. Ann Oncol Off J Eur Soc Med Oncol. 2017;28(9):2149–59.

Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 2014;15(6):569–79.

pubmed: 24739896

Siena S, Sartore-Bianchi A, Garcia-Carbonero R, Karthaus M, Smith D, Tabernero J, et al. Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. Ann Oncol Off J Eur Soc Med Oncol. 2018;29(1):119–26.

Pietrantonio F, Vernieri C, Siravegna G, Mennitto A, Berenato R, Perrone F, et al. Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23(10):2414–22.

Schrock AB, Pavlick D, Klempner SJ, Chung JH, Forcier B, Welsh A, et al. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with advanced cancers of the gastrointestinal tract or anus. Clin Cancer Res Off J Am Assoc Cancer Res. 2018;24(8):1881–90.

Siravegna G, Sartore-Bianchi A, Nagy RJ, Raghav K, Odegaard JI, Lanman RB, et al. Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25(10):3046–53.

Siravegna G, Lazzari L, Crisafulli G, Sartore-Bianchi A, Mussolin B, Cassingena A, et al. Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer. Cancer Cell. 2018;34(1):148-162.e7.

pubmed: 29990497

Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med. 2019;381(17):1632–43.

pubmed: 31566309

Cremolini C, Rossini D, Dell’Aquila E, Lonardi S, Conca E, Del Re M, et al. Rechallenge for patients With RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol. 2019;5(3):343–50.

pubmed: 30476968

Sartore-Bianchi A, Pietrantonio F, Lonardi S, Mussolin B, Rua F, Crisafulli G, et al. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nat Med. 2022;28(8):1612–8.

pubmed: 35915157 pmcid: 9386661

Listì A, Barraco N, Bono M, Insalaco L, Castellana L, Cutaia S, et al. Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer. Transl Cancer Res. 2019;8(Suppl 1):S55-63.

pubmed: 35117064 pmcid: 8799193

Fenizia F, De Luca A, Pasquale R, Sacco A, Forgione L, Lambiase M, et al. EGFR mutations in lung cancer: from tissue testing to liquid biopsy. Future Oncol Lond Engl. 2015;11(11):1611–23.

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–25.

pubmed: 29151359

Passaro A, Jänne PA, Mok T, Peters S. Overcoming therapy resistance in EGFR-mutant lung cancer. Nat Cancer. 2021;2(4):377–91.

pubmed: 35122001

Gristina V, Barraco N, La Mantia M, Castellana L, Insalaco L, Bono M, et al. Clinical potential of circulating cell-free DNA (cfDNA) for longitudinally monitoring clinical outcomes in the first-line setting of non-small-cell lung cancer (NSCLC): a real-world prospective study. Cancers. 2022;14(23):6013.

pubmed: 36497493 pmcid: 9735435

Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629–40.

pubmed: 27959700

Wu W, Haderk F, Bivona TG. Non-canonical thinking for targeting ALK-Fusion onco-proteins in lung cancer. Cancers. 2017;9(12):164.

pubmed: 29189709 pmcid: 5742812

Shaw AT, Solomon BJ, Besse B, Bauer TM, Lin CC, Soo RA, et al. ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37(16):1370–9.

Gristina V, La Mantia M, Iacono F, Galvano A, Russo A, Bazan V. The emerging therapeutic landscape of ALK inhibitors in non-small cell lung cancer. Pharm Basel Switz. 2020;13(12):474.

Li W, Liu JB, Hou LK, Yu F, Zhang J, Wu W, et al. Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring. Mol Cancer. 2022;21(1):25.

pubmed: 35057806 pmcid: 8772097

Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun. 2016;7:11815.

pubmed: 27283993 pmcid: 4906406

Patel A, Walters JN, Reuschel EL, Schultheis K, Parzych E, Gary EN, et al. Intradermal-delivered DNA vaccine induces durable immunity mediating a reduction in viral load in a rhesus macaque SARS-CoV-2 challenge model. Cell Rep Med. 2021;2(10):100420.

pubmed: 34604818 pmcid: 8479327

Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223–38.

pubmed: 28233803

Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO precision medicine working group. Ann Oncol Off J Eur Soc Med Oncol. 2020;31(11):1491–505.

Page RD, Drusbosky LM, Dada H, Raymond VM, Daniel DB, Divers SG, et al. Clinical outcomes for plasma-based comprehensive genomic profiling versus standard-of-care tissue testing in advanced non-small cell lung cancer. Clin Lung Cancer. 2022;23(1):72–81.

pubmed: 34782240

Hann HW, Jain S, Park G, Steffen JD, Song W, Su YH. Detection of urine DNA markers for monitoring recurrent hepatocellular carcinoma. Hepatoma Res. 2017;3:105–11.

pubmed: 28795155 pmcid: 5546802

Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol Off J Eur Soc Med Oncol. 2020;31(8):1056–64.

Scherer F. Capturing Tumor Heterogeneity and Clonal Evolution by Circulating Tumor DNA Profiling. Recent Results Cancer Res Fortschritte Krebsforsch Progres Dans Rech Sur Cancer. 2020;215:213–30.

Mack PC, Miao J, Redman MW, Moon J, Goldberg SB, Herbst RS, et al. Circulating tumor DNA kinetics predict progression-free and overall survival in EGFR TKI-treated patients with EGFR-mutant NSCLC (SWOG S1403). Clin Cancer Res Off J Am Assoc Cancer Res. 2022;28(17):3752–60.

Iwata H, Im SA, Masuda N, Im YH, Inoue K, Rai Y, et al. PALOMA-3: phase III trial of fulvestrant with or without palbociclib in premenopausal and postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer that progressed on prior endocrine therapy-safety and efficacy in asian patients. J Glob Oncol. 2017;3(4):289–303.

pubmed: 28831437 pmcid: 5560465

O’Leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K, et al. The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. Cancer Discov. 2018;8(11):1390–403.

pubmed: 30206110 pmcid: 6368247

Turner NC, Kingston B, Kilburn LS, Kernaghan S, Wardley AM, Macpherson IR, et al. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncol. 2020;21(10):1296–308.

pubmed: 32919527 pmcid: 7599319

Kingston B, Cutts RJ, Bye H, Beaney M, Walsh-Crestani G, Hrebien S, et al. Genomic profile of advanced breast cancer in circulating tumour DNA. Nat Commun. 2021;12(1):2423.

pubmed: 33893289 pmcid: 8065112

Hrebien S, Citi V, Garcia-Murillas I, Cutts R, Fenwick K, Kozarewa I, et al. Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial. Ann Oncol Off J Eur Soc Med Oncol. 2019;30(6):945–52.

Galvano A, Castellana L, Gristina V, La Mantia M, Insalaco L, Barraco N, et al. The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis. Ther Adv Med Oncol. 2022;14:17588359221110162.

pubmed: 36188485 pmcid: 9516428

Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open. 2019;2(5):e192535.

pubmed: 31050774 pmcid: 6503493

Passiglia F, Galvano A, Gristina V, Barraco N, Castiglia M, Perez A, et al. Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?-a trial-level meta-analysis in PD-L1 selected subgroups. Transl Lung Cancer Res. 2021;10(7):3106–19.

pubmed: 34430351 pmcid: 8350096

Sivapalan L, Murray JC, Canzoniero JV, Landon B, Jackson J, Scott S, et al. Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy. J Immunother Cancer. 2023;11(1):e005924.

pubmed: 36657818 pmcid: 9853269

Incorvaia L, Fanale D, Badalamenti G, Barraco N, Bono M, Corsini LR, et al. Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC). Adv Ther. 2019;36(10):2600–17.

pubmed: 31432460 pmcid: 6822831

Gristina V, Galvano A, Castellana L, Insalaco L, Cusenza S, Graceffa G, et al. Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses. Ther Adv Med Oncol. 2021;13:17588359211018018.

pubmed: 34646363 pmcid: 8504650

Yarchoan M, Hopkins A, Jaffee EM. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med. 2017;377(25):2500–1.

pubmed: 29262275 pmcid: 6549688

Pepe F, Pisapia P, Gristina V, Rocco D, Micheli M, Micheli P, et al. Tumor mutational burden on cytological samples: a pilot study. Cancer Cytopathol. 2021;129(6):460–7.

pubmed: 33378102

Hofman P, Heeke S, Alix-Panabières C, Pantel K. Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients? Ann Oncol Off J Eur Soc Med Oncol. 2019;30(9):1448–59.

Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin JM, Morrison RM, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021;371(6529):595–602.

pubmed: 33542131 pmcid: 8097968

Peters S, Dziadziuszko R, Morabito A, Felip E, Gadgeel SM, Cheema P, et al. Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial. Nat Med. 2022;28(9):1831–9.

pubmed: 35995953 pmcid: 9499854

He J, Kalinava N, Doshi P, Ma J, Pavlick DC, Albacker LA, Tukachinsky H, Fusaro G, Oxnard GR, Green G, Fabrizio D. Evaluation of tissue-and plasma-derived tumor mutational burden and genomic alterations of interest from the CheckMate 848 clinical trial. Cancer Res. 2022;82(12_Supplement):2139-39. https://doi.org/10.1158/1538-7445.AM2022-2139 .

Schenker M, Burotto M, Richardet M, Ciuleanu T, Goncalves A, Steeghs N, Schoffski P, Ascierto PA, Maio M, Lugowska I, Lupinacci L. CheckMate 848: a randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden. In: Cancer Research 2022 Jun 15 (Vol. 82, No. 12). 615 Chestnut St, 17th Floor, Philadelphia, PA 19106-4404 USA: Amer Assoc Cancer Research; 2022. https://doi.org/10.1158/1538-7445.AM2022-CT022 .

de Castro G, Rizvi NA, Schmid P, Syrigos K, Martin C, Yamamoto N, et al. NEPTUNE: phase 3 study of first-line durvalumab plus tremelimumab in patients with metastatic NSCLC. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2023;18(1):106–19.

Si H, Kuziora M, Quinn KJ, Helman E, Ye J, Liu F, et al. A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study. Clin Cancer Res Off J Am Assoc Cancer Res. 2021;27(6):1631–40.

Wang X, Li M. Correlate tumor mutation burden with immune signatures in human cancers. BMC Immunol. 2019;20:1–3. https://doi.org/10.1186/s12865-018-0285-5 .

doi: 10.1186/s12865-018-0285-5

Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, Bazhenova LA, Kurzrock R. Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor–based immunotherapy. Clin Cancer Res. 2017;23(19):5729–36. https://doi.org/10.1158/1078-0432.CCR-17-1439 .

doi: 10.1158/1078-0432.CCR-17-1439 pubmed: 28972084 pmcid: 5678984

Georgiadis A, Durham JN, Keefer LA, Bartlett BR, Zielonka M, Murphy D, et al. Noninvasive detection of microsatellite instability and high tumor mutation burden in cancer patients treated with PD-1 blockade. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25(23):7024–34.

Bratman SV, Yang SC, Iafolla MA, Liu Z, Hansen AR, Bedard PL, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer. 2020;1(9):873–81. https://doi.org/10.1038/s43018-020-0096-5 .

doi: 10.1038/s43018-020-0096-5 pubmed: 35121950

Váraljai R, Wistuba-Hamprecht K, Seremet T, Diaz JMS, Nsengimana J, Sucker A, et al. Application of circulating cell-free tumor DNA Profiles for therapeutic monitoring and outcome prediction in genetically heterogeneous metastatic melanoma. JCO Precis Oncol. 2019;3:1–10.

Guibert N, Jones G, Beeler JF, Plagnol V, Morris C, Mourlanette J, et al. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer. Lung Cancer Amst Neth. 2019;137:1–6.

Goldberg SB, Narayan A, Kole AJ, Decker RH, Teysir J, Carriero NJ, et al. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA. Clin Cancer Res Off J Am Assoc Cancer Res. 2018;24(8):1872–80.

Kim WT, Kim YH, Jeong P, Seo SP, Kang HW, Kim YJ, et al. Urinary cell-free nucleic acid IQGAP3: a new non-invasive diagnostic marker for bladder cancer. Oncotarget. 2018;9(18):14354–65.

pubmed: 29581849 pmcid: 5865675

Ilié M, Szafer-Glusman E, Hofman V, Chamorey E, Lalvée S, Selva E, et al. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. Ann Oncol Off J Eur Soc Med Oncol. 2018;29(1):193–9.

Guibert N, Delaunay M, Lusque A, Boubekeur N, Rouquette I, Clermont E, et al. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab. Lung Cancer Amst Neth. 2018;120:108–12.

Nicolazzo C, Raimondi C, Mancini M, Caponnetto S, Gradilone A, Gandini O, et al. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. Sci Rep. 2016;6:31726.

pubmed: 27553175 pmcid: 4995431

Hogan SA, Courtier A, Cheng PF, Jaberg-Bentele NF, Goldinger SM, Manuel M, et al. Peripheral blood TCR repertoire profiling may facilitate patient stratification for immunotherapy against melanoma. Cancer Immunol Res. 2019;7(1):77–85.

pubmed: 30425105

Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med. 2016;22(4):433–8.

pubmed: 26901407 pmcid: 7446107

Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545(7652):60–5.

pubmed: 28397821 pmcid: 5554367

Bian B, Fanale D, Dusetti N, Roque J, Pastor S, Chretien AS, et al. Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma. Oncoimmunology. 2019;8(4):e1561120.

pubmed: 30906655 pmcid: 6422385

Incorvaia L, Badalamenti G, Rinaldi G, Iovanna JL, Olive D, Swayden M, et al. Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma? Ther Adv Med Oncol. 2019;11:1758835919848872.

pubmed: 31205506 pmcid: 6535916

Fanale D, Incorvaia L, Badalamenti G, De Luca I, Algeri L, Bonasera A, et al. Prognostic role of plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in patients affected by metastatic gastrointestinal stromal tumors: can immune checkpoints act as a sentinel for short-term survival? Cancers. 2021;13(9):2118.

pubmed: 33925671 pmcid: 8125172

Incorvaia L, Fanale D, Badalamenti G, Porta C, Olive D, De Luca I, et al. Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions. Oncoimmunology. 2020;9(1):1832348.

pubmed: 33178494 pmcid: 7595592

Incorvaia L, Fanale D, Badalamenti G, Brando C, Bono M, De Luca I, et al. A «Lymphocyte MicroRNA Signature» as predictive biomarker of immunotherapy response and plasma PD-1/PD-L1 expression levels in patients with metastatic renal cell carcinoma: pointing towards epigenetic reprogramming. Cancers. 2020;12(11):3396.

pubmed: 33207823 pmcid: 7697734

Incorvaia L, Rinaldi G, Badalamenti G, Cucinella A, Brando C, Madonia G, et al. Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay. Ther Adv Med Oncol. 2023;15:17588359231151844.

Galvano A, Gristina V, Malapelle U, Pisapia P, Pepe F, Barraco N, et al. The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials. ESMO Open. 2021;6(3):100124.

pubmed: 33940346 pmcid: 8111593

Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973–85.

pubmed: 35403841 pmcid: 9844511

Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24(9):1449–58.

pubmed: 30013197

He Y, Zhang X, Zhu M, He W, Hua H, Ye F, et al. Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer. J Transl Med. 2023;21(1):25.

pubmed: 36639643 pmcid: 9837921

Mathew M, Zade M, Mezghani N, Patel R, Wang Y, Momen-Heravi F. Extracellular Vesicles as Biomarkers in Cancer Immunotherapy. Cancers. 2020;12(10):2825.

pubmed: 33007968 pmcid: 7600903

Lane RE, Korbie D, Hill MM, Trau M. Extracellular vesicles as circulating cancer biomarkers: opportunities and challenges. Clin Transl Med. 2018;7(1):14.

pubmed: 29855735 pmcid: 5981152

Liu SY, Liao Y, Hosseinifard H, Imani S, Wen QL. Diagnostic role of extracellular vesicles in cancer: a comprehensive systematic review and meta-analysis. Front Cell Dev Biol. 2021;9:705791.

pubmed: 34722499 pmcid: 8555429

Cammarata G, Barraco N, Giusti I, Gristina V, Dolo V, Taverna S. Extracellular vesicles-ceRNAs as ovarian cancer biomarkers: looking into circRNA-miRNA-mRNA code. Cancers. 2022;14(14):3404.

pubmed: 35884464 pmcid: 9324482

Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.

pubmed: 32029601 pmcid: 7717626

Majood M, Rawat S, Mohanty S. Delineating the role of extracellular vesicles in cancer metastasis: a comprehensive review. Front Immunol. 2022;13:966661.

pubmed: 36059497 pmcid: 9439583

Soekmadji C, Li B, Huang Y, Wang H, An T, Liu C, et al. The future of extracellular vesicles as theranostics - an ISEV meeting report. J Extracell Vesicle. 2020;9(1):1809766.

Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7(1):1535750.

pubmed: 30637094 pmcid: 6322352

Kang T, Atukorala I, Mathivanan S. Biogenesis of extracellular vesicles. Subcell Biochem. 2021;97:19–43.

pubmed: 33779912

Palviainen M, Saraswat M, Varga Z, Kitka D, Neuvonen M, Puhka M, et al. Extracellular vesicles from human plasma and serum are carriers of extravesicular cargo-Implications for biomarker discovery. PLoS ONE. 2020;15(8):e0236439.

pubmed: 32813744 pmcid: 7446890

Witwer KW, Buzás EI, Bemis LT, Bora A, Lässer C, Lötvall J, et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles. 2013;2.

Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol. 1967;13(3):269–88.

pubmed: 6025241

Amintas S, Vendrely V, Dupin C, Buscail L, Laurent C, Bournet B, et al. Next-generation cancer biomarkers: extracellular vesicle DNA as a circulating surrogate of tumor DNA. Front Cell Dev Biol. 2020;8:622048.

pubmed: 33604335

Cai X, Janku F, Zhan Q, Fan JB. Accessing genetic information with liquid biopsies. Trends Genet TIG. 2015;31(10):564–75.

pubmed: 26450339

Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527(7578):329–35.

pubmed: 26524530 pmcid: 4788391

Leetanaporn K, Hanprasertpong J, Navakanitworakul R. Molecular insights and clinical impacts of extracellular vesicles in cancer. Oncol Rev. 2021;15(2):542.

pubmed: 34667488 pmcid: 8477311

Hosseini K, Ranjbar M, Pirpour Tazehkand A, Asgharian P, Montazersaheb S, Tarhriz V, et al. Evaluation of exosomal non-coding RNAs in cancer using high-throughput sequencing. J Transl Med. 2022;20(1):30.

pubmed: 35033106 pmcid: 8760667

de Miguel-Perez D, Russo A, Arrieta O, Ak M, Barron F, Gunasekaran M, et al. Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer. J Exp Clin Cancer Res CR. 2022;41(1):186.

pubmed: 35650597

Svedman FC, Lohcharoenkal W, Bottai M, Brage SE, Sonkoly E, Hansson J, et al. Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastastic cutaneous malignant melanoma. PLoS ONE. 2018;13(11):e0206942.

pubmed: 30399176 pmcid: 6219796

Corcoran C, Rani S, O’Driscoll L. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. Prostate. 2014;74(13):1320–34.

pubmed: 25053345

Vinik Y, Ortega FG, Mills GB, Lu Y, Jurkowicz M, Halperin S, et al. Proteomic analysis of circulating extracellular vesicles identifies potential markers of breast cancer progression, recurrence, and response. Sci Adv. 2020;6(40):eaba5714.

pubmed: 33008904 pmcid: 7852393

Bernard V, Kim DU, San Lucas FA, Castillo J, Allenson K, Mulu FC, et al. Circulating nucleic acids are associated with outcomes of patients with pancreatic cancer. Gastroenterology. 2019;156(1):108-118.e4.

pubmed: 30240661

Castellanos-Rizaldos E, Grimm DG, Tadigotla V, Hurley J, Healy J, Neal PL, et al. Exosome-based detection of EGFR T790M in plasma from non-small cell lung cancer patients. Clin Cancer Res Off J Am Assoc Cancer Res. 2018;24(12):2944–50.

Ma C, Jiang F, Ma Y, Wang J, Li H, Zhang J. Isolation and detection technologies of extracellular vesicles and application on cancer diagnostic. Dose-Response Publ Int Hormesis Soc. 2019;17(4):1559325819891004.

Heitzer E, Haque IS, Roberts CES, Speicher MR. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet. 2019;20(2):71–88.

pubmed: 30410101

Tivey A, Church M, Rothwell D, Dive C, Cook N. Circulating tumour DNA - looking beyond the blood. Nat Rev Clin Oncol. 2022;19(9):600–12.

pubmed: 35915225 pmcid: 9341152

Oshi M, Murthy V, Takahashi H, Huyser M, Okano M, Tokumaru Y, et al. Urine as a source of liquid biopsy for cancer. Cancers. 2021;13(11):2652.

pubmed: 34071230 pmcid: 8199052

Green EA, Li R, Albiges L, Choueiri TK, Freedman M, Pal S, et al. Clinical utility of cell-free and circulating tumor DNA in kidney and bladder cancer: a critical review of current literature. Eur Urol Oncol. 2021;4(6):893–903.

pubmed: 33975782

Wang X, Meng Q, Wang C, Li F, Zhu Z, Liu S, et al. Investigation of transrenal KRAS mutation in late stage NSCLC patients correlates to disease progression. Biomark Biochem Indic Expo Response Susceptibility Chem. 2017;22(7):654–60.

Xie F, Li P, Gong J, Tan H, Ma J. Urinary cell-free DNA as a prognostic marker for KRAS-positive advanced-stage NSCLC. Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex. 2018;20(5):591–8.

Wang Z, Wang X, Zhang D, Yu Y, Cai L, Zhang C. Long non-coding RNA urothelial carcinoma-associated 1 as a tumor biomarker for the diagnosis of urinary bladder cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2017;39(6):1010428317709990.

Yu H, Han L, Yuan J, Sun Y. Circulating tumor cell free DNA from plasma and urine in the clinical management of colorectal cancer. Cancer Biomark Sect Dis Markers. 2020;27(1):29–37.

Tian F, Liao Y, Zhang Y. Variations in transrenal DNA and comparison with plasma DNA as a diagnostic marker for colorectal cancer. Int J Biol Markers. 2017;32(4):e434-40.

pubmed: 28708207

Zuo Z, Tang J, Cai X, Ke F, Shi Z. Probing of breast cancer using a combination of plasma and urinary circulating cell-free DNA. Biosci Rep. 2020;40(11):BSR20194306.

pubmed: 33044511 pmcid: 7610146

Zhang R, Zang J, Xie F, Zhang Y, Wang Y, Jing Y, et al. Urinary molecular pathology for patients with newly diagnosed urothelial bladder cancer. J Urol. 2021;206(4):873–84.

pubmed: 34061567

Oto J, Santillana N, Solmoirago MJ, Pérez AJ, Sánchez GJV, Plana E, et al. Mp21-11 diagnostic and prognostic value of urine circulating cell-free dna in renal cell carcinoma. J Urol. 2019;201(Supplement 4):e296–e296.

Springer SU, Chen CH, Rodriguez Pena MDC, Li L, Douville C, Wang Y, et al. Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy. eLife. 2018;7:e32143.

pubmed: 29557778 pmcid: 5860864

Dudley JC, Schroers-Martin J, Lazzareschi DV, Shi WY, Chen SB, Esfahani MS, et al. Detection and surveillance of bladder cancer using urine tumor DNA. Cancer Discov. 2019;9(4):500–9.

pubmed: 30578357

Nuzzo PV, Berchuck JE, Korthauer K, Spisak S, Nassar AH, Abou Alaiwi S, et al. Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. Nat Med. 2020;26(7):1041–3.

pubmed: 32572266 pmcid: 8288043

Casadio V, Calistri D, Salvi S, Gunelli R, Carretta E, Amadori D, et al. Urine cell-free DNA integrity as a marker for early prostate cancer diagnosis: a pilot study. BioMed Res Int. 2013;2013:270457.

pubmed: 23509700 pmcid: 3586456

McKiernan J, Donovan MJ, O’Neill V, Bentink S, Noerholm M, Belzer S, et al. A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy. JAMA Oncol. 2016;2(7):882–9.

pubmed: 27032035

Sanguedolce F, Cormio A, Brunelli M, D’Amuri A, Carrieri G, Bufo P, et al. Urine TMPRSS2: ERG fusion transcript as a biomarker for prostate cancer: literature review. Clin Genitourin Cancer. 2016;14(2):117–21.

pubmed: 26774207

Groskopf J, Aubin SMJ, Deras IL, Blase A, Bodrug S, Clark C, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem. 2006;52(6):1089–95.

pubmed: 16627561

Whitman EJ, Groskopf J, Ali A, Chen Y, Blase A, Furusato B, et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol. 2008;180(5):1975–8 discussion 1978-1979.

pubmed: 18801539

Tutrone R, Donovan MJ, Torkler P, Tadigotla V, McLain T, Noerholm M, et al. Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2–10 ng/mL. Prostate Cancer Prostatic Dis. 2020;23(4):607–14.

pubmed: 32382078 pmcid: 7655505

Hendriks RJ, van der Leest MMG, Israël B, Hannink G, YantiSetiasti A, Cornel EB, et al. Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men. Prostate Cancer Prostatic Dis. 2021;24(4):1110–9.

pubmed: 33941866 pmcid: 8616754

Srivastava AK, Singh PK, Rath SK, Dalela D, Goel MM, Bhatt MLB. Appraisal of diagnostic ability of UCA1 as a biomarker of carcinoma of the urinary bladder. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2014;35(11):11435–42.

Berz D, Raymond VM, Garst JH, Erlander MG. Non-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer. Exp Hematol Oncol. 2015;5:24.

pubmed: 27508108

Chen W, Liao Y, Yang C, Fang Z, Liu B, Zheng X, et al. Potential use of transrenal DNA for non-invasive monitoring and prognosis of colorectal cancer. Biomark Biochem Indic Expo Response Susceptibility Chem. 2019;24(6):524–9.

Smith CG, Moser T, Mouliere F, Field-Rayner J, Eldridge M, Riediger AL, et al. Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors. Genome Med. 2020;12(1):23.

pubmed: 32111235 pmcid: 7048087

Silva R, Moran B, Russell NM, Fahey C, Vlajnic T, Manecksha RP, et al. Evaluating liquid biopsies for methylomic profiling of prostate cancer. Epigenetics. 2020;15(6–7):715–27.

pubmed: 32000564 pmcid: 7574384

Augustus E, Van Casteren K, Sorber L, van Dam P, Roeyen G, Peeters M, et al. The art of obtaining a high yield of cell-free DNA from urine. PLoS ONE. 2020;15(4):e0231058.

pubmed: 32251424 pmcid: 7135229

Kim WT, Jeong P, Yan C, Kim YH, Lee IS, Kang HW, et al. UBE2C cell-free RNA in urine can discriminate between bladder cancer and hematuria. Oncotarget. 2016;7(36):58193–202.

pubmed: 27528424 pmcid: 5295424

Qu L, Ding J, Chen C, Wu ZJ, Liu B, Gao Y, et al. Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA. Cancer Cell. 2016;29(5):653–68.

pubmed: 27117758

Iliev R, Fedorko M, Machackova T, Mlcochova H, Svoboda M, Pacik D, et al. Expression levels of PIWI-interacting RNA, piR-823, are deregulated in tumor tissue, blood serum and urine of patients with renal cell carcinoma. Anticancer Res. 2016;36(12):6419–23.

pubmed: 27919963

Chen X, Chen RX, Wei WS, Li YH, Feng ZH, Tan L, et al. PRMT5 Circular RNA promotes metastasis of urothelial carcinoma of the bladder through sponging miR-30c to induce epithelial-mesenchymal transition. Clin Cancer Res Off J Am Assoc Cancer Res. 2018;24(24):6319–30.

Zimmermann BG, Park NJ, Wong DT. Genomic targets in saliva. Ann N Y Acad Sci. 2007;1098:184–91.

pubmed: 17435127 pmcid: 2910758

Kaczor-Urbanowicz KE, Wei F, Rao SL, Kim J, Shin H, Cheng J, et al. Clinical validity of saliva and novel technology for cancer detection. Biochim Biophys Acta Rev Cancer. 2019;1872(1):49–59.

pubmed: 31152821 pmcid: 6692231

Sethi S, Benninger MS, Lu M, Havard S, Worsham MJ. Noninvasive molecular detection of head and neck squamous cell carcinoma: an exploratory analysis. Diagn Mol Pathol Am J Surg Pathol Part B. 2009;18(2):81–7.

Ahn SM, Chan JYK, Zhang Z, Wang H, Khan Z, Bishop JA, et al. Saliva and plasma quantitative polymerase chain reaction-based detection and surveillance of human papillomavirus-related head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2014;140(9):846–54.

pubmed: 25078109 pmcid: 4313904

Hanna GJ, Lau CJ, Mahmood U, Supplee JG, Mogili AR, Haddad RI, et al. Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer. Oral Oncol. 2019;95:120–6.

pubmed: 31345379

Ding S, Song X, Geng X, Liu L, Ma H, Wang X, et al. Saliva-derived cfDNA is applicable for EGFR mutation detection but not for quantitation analysis in non-small cell lung cancer. Thorac Cancer. 2019;10(10):1973–83.

pubmed: 31441578 pmcid: 6775000

Wei F, Lin CC, Joon A, Feng Z, Troche G, Lira ME, et al. Noninvasive saliva-based EGFR gene mutation detection in patients with lung cancer. Am J Respir Crit Care Med. 2014;190(10):1117–26.

pubmed: 25317990 pmcid: 5447327

Pu D, Liang H, Wei F, Akin D, Feng Z, Yan Q, et al. Evaluation of a novel saliva-based epidermal growth factor receptor mutation detection for lung cancer: a pilot study. Thorac Cancer. 2016;7(4):428–36.

pubmed: 27385985 pmcid: 4930962

Li F, Wei F, Liao W, Huang WL, Lin C chung, Chia D, et al. EFIRM liquid biopsy (eLB): Detection of ultra-short circulating tumor DNA (usctDNA) in plasma and saliva of non-small cell lung cancer (NSCLC) patients. J Clin Oncol. 2018;36(15_suppl):e24062–e24062.

Li F, Wei F, Huang WL, Lin CC, Li L, Shen MM, et al. Ultra-short circulating tumor DNA (usctDNA) in plasma and saliva of non-small cell lung cancer (NSCLC) patients. Cancers. 2020;12(8):2041.

pubmed: 32722209 pmcid: 7464208

Li Y, St John MAR, Zhou X, Kim Y, Sinha U, Jordan RCK, et al. Salivary transcriptome diagnostics for oral cancer detection. Clin Cancer Res Off J Am Assoc Cancer Res. 2004;10(24):8442–50.

Elashoff D, Zhou H, Reiss J, Wang J, Xiao H, Henson B, et al. Prevalidation of salivary biomarkers for oral cancer detection. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2012;21(4):664–72.

Bu J, Bu X, Liu B, Chen F, Chen P. Increased Expression of Tissue/Salivary Transgelin mRNA Predicts Poor Prognosis in Patients with Oral Squamous Cell Carcinoma (OSCC). Med Sci Monit Int Med J Exp Clin Res. 2015;21:2275–81.

Chai RC, Lim Y, Frazer IH, Wan Y, Perry C, Jones L, et al. A pilot study to compare the detection of HPV-16 biomarkers in salivary oral rinses with tumour p16(INK4a) expression in head and neck squamous cell carcinoma patients. BMC Cancer. 2016;16:178.

pubmed: 26940728 pmcid: 4778285

Han B, Chao J, Yao H. Circular RNA and its mechanisms in disease: from the bench to the clinic. Pharmacol Ther. 2018;187:31–44.

pubmed: 29406246

Zahran F, Ghalwash D, Shaker O, Al-Johani K, Scully C. Salivary microRNAs in oral cancer. Oral Dis. 2015;21(6):739–47.

pubmed: 25784212

Wu L, Zheng K, Yan C, Pan X, Liu Y, Liu J, et al. Genome-wide study of salivary microRNAs as potential noninvasive biomarkers for detection of nasopharyngeal carcinoma. BMC Cancer. 2019;19(1):843.

pubmed: 31455274 pmcid: 6712819

Uma Maheswari TN, Nivedhitha MS, Ramani P. Expression profile of salivary micro RNA-21 and 31 in oral potentially malignant disorders. Braz Oral Res. 2020;34:e002.

pubmed: 32049107

Ahmad P, Sana J, Slavik M, Gurin D, Radova L, Gablo NA, et al. MicroRNA-15b-5p predicts locoregional relapse in head and neck carcinoma patients treated with intensity-modulated radiotherapy. Cancer Genomics Proteomics. 2019;16(2):139–46.

pubmed: 30850365 pmcid: 6489689

Tang H, Wu Z, Zhang J, Su B. Salivary lncRNA as a potential marker for oral squamous cell carcinoma diagnosis. Mol Med Rep. 2013;7(3):761–6.

pubmed: 23292713

Bahn JH, Zhang Q, Li F, Chan TM, Lin X, Kim Y, et al. The landscape of microRNA, Piwi-interacting RNA, and circular RNA in human saliva. Clin Chem. 2015;61(1):221–30.

pubmed: 25376581

Zhao SY, Wang J, Ouyang SB, Huang ZK, Liao L. Salivary Circular RNAs Hsa_Circ_0001874 and Hsa_Circ_0001971 as Novel Biomarkers for the Diagnosis of Oral Squamous Cell Carcinoma. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2018;47(6):2511–21.

Li K, Lin Y, Luo Y, Xiong X, Wang L, Durante K, et al. A signature of saliva-derived exosomal small RNAs as predicting biomarker for esophageal carcinoma: a multicenter prospective study. Mol Cancer. 2022;21(1):21.

pubmed: 35042519 pmcid: 8764835

Patel A, Patel S, Patel P, Tanavde V. Saliva based liquid biopsies in head and neck cancer: how far are we from the clinic? Front Oncol. 2022;12:828434.

pubmed: 35387114 pmcid: 8977527

Greither T, Vorwerk F, Kappler M, Bache M, Taubert H, Kuhnt T, et al. Salivary miR-93 and miR-200a as post-radiotherapy biomarkers in head and neck squamous cell carcinoma. Oncol Rep. 2017;38(2):1268–75.

pubmed: 28677748

Yuvaraj M, Udayakumar K, Jayanth V, Prakasa Rao A, Bharanidharan G, Koteeswaran D, et al. Fluorescence spectroscopic characterization of salivary metabolites of oral cancer patients. J Photochem Photobiol B. 2014;130:153–60.

pubmed: 24333763

Deo PN, Deshmukh R. Oral microbiome and oral cancer - The probable nexus. J Oral Maxillofac Pathol JOMFP. 2020;24(2):361–7.

pubmed: 33456248

Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME, Colorectal Cancer Study Group. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med. 2004;351(26):2704–14.

pubmed: 15616205

Prince M, Lester L, Chiniwala R, Berger B. Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant medicare patients. World J Gastroenterol. 2017;23(3):464–71.

pubmed: 28210082 pmcid: 5291851

Redwood DG, Asay ED, Blake ID, Sacco PE, Christensen CM, Sacco FD, et al. Stool DNA testing for screening detection of colorectal neoplasia in Alaska native people. Mayo Clin Proc. 2016;91(1):61–70.

pubmed: 26520415

Naber SK, Knudsen AB, Zauber AG, Rutter CM, Fischer SE, Pabiniak CJ, et al. Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries. PLoS ONE. 2019;14(9):e0220234.

pubmed: 31483796 pmcid: 6726189

Caldas C, Hahn SA, Hruban RH, Redston MS, Yeo CJ, Kern SE. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res. 1994;54(13):3568–73.

pubmed: 8012983

Youssef O, Sarhadi V, Ehsan H, Böhling T, Carpelan-Holmström M, Koskensalo S, et al. Gene mutations in stool from gastric and colorectal neoplasia patients by next-generation sequencing. World J Gastroenterol. 2017;23(47):8291–9.

pubmed: 29307989 pmcid: 5743500

Allen-Vercoe E, Coburn B. A microbiota-derived metabolite augments cancer immunotherapy responses in mice. Cancer Cell. 2020;38(4):452–3.

pubmed: 32976777

Xu X, Lv J, Guo F, Li J, Jia Y, Jiang D, et al. Gut microbiome influences the efficacy of PD-1 antibody immunotherapy on MSS-type colorectal cancer via metabolic pathway. Front Microbiol. 2020;11:814.

pubmed: 32425919 pmcid: 7212380

Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2021;371(6529):602–9.

pubmed: 33303685

Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(6264):1084–9.

pubmed: 26541606 pmcid: 4873287

Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079–84.

pubmed: 26541610 pmcid: 4721659

Wu CW, Ng SSM, Dong YJ, Ng SC, Leung WW, Lee CW, et al. Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut. 2012;61(5):739–45.

pubmed: 21930727

Raut JR, Schöttker B, Holleczek B, Guo F, Bhardwaj M, Miah K, et al. A microRNA panel compared to environmental and polygenic scores for colorectal cancer risk prediction. Nat Commun. 2021;12(1):4811.

pubmed: 34376648 pmcid: 8355103

Liu H, Gong W, Lou J, Ju H, Yin X, Liu Y, et al. MicroRNA-21 and microRNA-146a identification in stool and its clinical significance in colorectal neoplasms. 2016;9:16441–9

Bastaminejad S, Taherikalani M, Ghanbari R, Akbari A, Shabab N, Saidijam M. Investigation of MicroRNA-21 expression levels in serum and stool as a potential non-invasive biomarker for diagnosis of colorectal cancer. Iran Biomed J. 2017;21(2):106–13.

pubmed: 27432735 pmcid: 5274709

Phua LC, Chue XP, Koh PK, Cheah PY, Chan ECY, Ho HK. Global fecal microRNA profiling in the identification of biomarkers for colorectal cancer screening among Asians. Oncol Rep. 2014;32(1):97–104.

pubmed: 24841830

Duran-Sanchon S, Moreno L, Gómez-Matas J, Augé JM, Serra-Burriel M, Cuatrecasas M, et al. Fecal MicroRNA-based algorithm increases effectiveness of fecal immunochemical test-based screening for colorectal cancer. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2021;19(2):323-330.e1.

Duran-Sanchon S, Moreno L, Augé JM, Serra-Burriel M, Cuatrecasas M, Moreira L, et al. Identification and validation of MicroRNA profiles in fecal samples for detection of colorectal cancer. Gastroenterology. 2020;158(4):947-957.e4.

pubmed: 31622624

Gharib E, Nazemalhosseini-Mojarad E, Baghdar K, Nayeri Z, Sadeghi H, Rezasoltani S, et al. Identification of a stool long non-coding RNAs panel as a potential biomarker for early detection of colorectal cancer. J Clin Lab Anal. 2021;35(2):e23601.

pubmed: 33094859

Zhao Z, Zhu A, Bhardwaj M, Schrotz-King P, Brenner H. Fecal microRNAs, fecal microRNA Panels, or combinations of fecal microRNAs with fecal hemoglobin for early detection of colorectal cancer and its precursors: a systematic review. Cancers. 2021;14(1):65.

pubmed: 35008229 pmcid: 8750731

Klaassen CHW, Jeunink MAF, Prinsen CFM, Ruers TJM, Tan ACITL, Strobbe LJA, et al. Quantification of human DNA in feces as a diagnostic test for the presence of colorectal cancer. Clin Chem. 2003;49(7):1185–7.

pubmed: 12816918

van Dam L, Korfage IJ, Kuipers EJ, Hol L, van Roon AHC, Reijerink JCIY, et al. What influences the decision to participate in colorectal cancer screening with faecal occult blood testing and sigmoidoscopy? Eur J Cancer Oxf Engl 1990. 2013;49(10):2321–30.

Osborne JM, Flight I, Wilson CJ, Chen G, Ratcliffe J, Young GP. The impact of sample type and procedural attributes on relative acceptability of different colorectal cancer screening regimens. Patient Prefer Adherence. 2018;12:1825–36.

pubmed: 30271126 pmcid: 6154741

Network approach in liquidomics landscape.

Journal

Informations de publication

Résumé

Identifiants

Substances chimiques

Types de publication

Langues

Sous-ensembles de citation

Pagination

Informations de copyright

Références

Auteurs

Daniele Santini (D)

Andrea Botticelli (A)

Antonio Galvano (A)

Michele Iuliani (M)

Lorena Incorvaia (L)

Valerio Gristina (V)

Chiara Taffon (C)

Simone Foderaro (S)

Elisa Paccagnella (E)

Sonia Simonetti (S)

Federico Fazio (F)

Simone Scagnoli (S)

Giulia Pomati (G)

Francesco Pantano (F)

Giuseppe Perrone (G)

Elena De Falco (E)

Antonio Russo (A)

Gian Paolo Spinelli (GP)

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Smoking Cessation and Incident Cardiovascular Disease.

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Classifications MeSH